ITIF-AR VR在医疗保健领域的潜力（英）

itif.org AR/VR's Potential in Health Care ALEX AMBROSE | JUNE 2025 AR/VR innovation needs to accelerate in order to meet the critical demands of health care. Policymakers should empower and fund immersive technologies in the health-care industry because of the long-term cost saving benefits and positive impact on patient care. KEY TAKEAWAYS  Immersive technologies enhance traditional methods of health care and present new treatment options to explore, ultimately saving money and producing better outcomes for patient health.  From medical student training to physical therapy rehabilitation, VR technologies provide patients and providers with safer and more personalized experiences than they would receive in traditional care settings.  AR/VR can address critical health-care industry challenges such as provider burnout, care access disparities, and care deserts.  American companies dominate the AR/VR market—a market expected to grow over 10 times in the next decade—and health-care applications remains a key driver of U.S. innovation.  For this innovation to continue, Congress should refine the Food and Drug Administration and Centers for Medicaid and Medicare Services’ scope to better include immersive technologies in their approval pipelines. INFORMATION TECHNOLOGY & INNOVATION FOUNDATION | JUNE 2025 PAGE 2 CONTENTS Key Takeaways ................................................................................................................... 1 Introduction ....................................................................................................................... 3 Value of AR/VR in Health care ............................................................................................. 4 Who Is Using AR/VR In Health Care ..................................................................................... 5 Doctors and Practitioners ................................................................................................. 5 Mental Health Practitioners............................................................................................ 11 Education .................................................................................................................... 13 Pharmaceutical and Medical Device Researchers and Developers ....................................... 16 Patients ....................................................................................................................... 18 Barriers and Risks to Adoption ........................................................................................... 21 Barriers ........................................................................................................................ 21 Risks ........................................................................................................................... 23 Policy Recommendations .................................................................................................. 25